Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Helgason

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|September 14, 2006
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancerH H Helgason, C M F Kruijtzer, A D R Huitema, et al.
Environmental Science & Technology|October 16, 2020
Contrasting Spatial and Seasonal Trends of Methylmercury Exposure Pathways of Arctic Seabirds: Combination of Large-Scale Tracking and Stable Isotopic ApproachesMarina Renedo, David Amouroux, Céline Albert, et al.
Current Clinical Pharmacology|November 14, 2013
Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancerHelgi H Helgason, Stijn L W Koolen, Erik van Werkhoven, et al.
British Journal of Cancer|July 3, 2008
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancerA A M van der Veldt, E Boven, H H Helgason, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2019
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimusInge M Werter, Charlotte M Huijts, Sinéad M Lougheed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primaryHugo M Horlings, Ryan K van Laar, Jan-Martijn Kerst, et al.
Clinical Therapeutics|April 5, 2011
Consensus-based evaluation of clinical significance and management of anticancer drug interactionsFrank G A Jansman, An K L Reyners, Eric N van Roon, et al.
Molecular Oncology|May 13, 2023
mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancerKhrystany T Isebia, Bianca Mostert, Teoman Deger, et al.
Leukemia|January 31, 2014
The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasmsA Oddsson, S Y Kristinsson, H Helgason, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2025
Demographic responses of North Atlantic seabirds to seasonal ocean warmingKate Layton-Matthews, Charlotte E Regan, Manuel Ballesteros, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|September 14, 2006
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancerH H Helgason, C M F Kruijtzer, A D R Huitema, et al.
Environmental Science & Technology|October 16, 2020
Contrasting Spatial and Seasonal Trends of Methylmercury Exposure Pathways of Arctic Seabirds: Combination of Large-Scale Tracking and Stable Isotopic ApproachesMarina Renedo, David Amouroux, Céline Albert, et al.
Current Clinical Pharmacology|November 14, 2013
Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancerHelgi H Helgason, Stijn L W Koolen, Erik van Werkhoven, et al.
British Journal of Cancer|July 3, 2008
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancerA A M van der Veldt, E Boven, H H Helgason, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2019
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimusInge M Werter, Charlotte M Huijts, Sinéad M Lougheed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primaryHugo M Horlings, Ryan K van Laar, Jan-Martijn Kerst, et al.
Clinical Therapeutics|April 5, 2011
Consensus-based evaluation of clinical significance and management of anticancer drug interactionsFrank G A Jansman, An K L Reyners, Eric N van Roon, et al.
Molecular Oncology|May 13, 2023
mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancerKhrystany T Isebia, Bianca Mostert, Teoman Deger, et al.
Leukemia|January 31, 2014
The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasmsA Oddsson, S Y Kristinsson, H Helgason, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2025
Demographic responses of North Atlantic seabirds to seasonal ocean warmingKate Layton-Matthews, Charlotte E Regan, Manuel Ballesteros, et al.
Pageof 6